28 feb: Tillægsprospekt
28 feb: Insideres handel
28-02-2017 18:22:29

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Relateret indhold
29 mar - 
Genmab dropper nu også nyheder på dansk
29 mar - 
Aktier/åbning: Mærsk trækker eliteindeks ned mens Carls..
29 mar - 
Aktier/tendens: Vestas kan komme i fokus i lysegrønt ma..
Relateret debat
08:28 - 
solsen:   "Man starter ikke et forsøg op, h..
07:52 - 
Janssens:   http://medwatch.dk/secure/Medicinal___..
07:47 - 
Nyt forsøg under opstart, taget fra proinvestor...

Company Announcement

Copenhagen, Denmark; February 28, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 385,087 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

  • 450 shares at DKK 31.75,

  • 2,750 shares at DKK 40.41,

  • 750 shares at DKK 45.24,

  • 3,750 shares at DKK 46.74,

  • 300 shares at DKK 66.60,

  • 375 shares at DKK 67.50,

  • 4,250 shares at DKK 68.65,

  • 1,250 shares at DKK 79.25,

  • 25,000 shares at DKK 80.55,

  • 187 shares at DKK 98,

  • 16,110 shares at DKK 129.75,

  • 8,500 shares at DKK 174,

  • 1,844 shares at DKK 210,

  • 8,200 shares at DKK 220.40,

  • 575 shares at DKK 225.30,

  • 40,115 shares at DKK 225.90,

  • 3,425 shares at DKK 231.50,

  • 350 shares at DKK 234,

  • 400 shares at DKK 234.75,

  • 41,000 shares at DKK 246,

  • 67,490 shares at DKK 254,

  • 35,050 shares at DKK 272,

  • 8,550 shares at DKK 326.50,

  • 125 shares at DKK 329,

  • 14,299 shares at DKK 337.40,

  • 50,228 shares at DKK 352.50,

  • 40,250 shares at DKK 364,

  • 500 shares at DKK 466.20,

  • 175 shares at DKK 623.50,

  • 2,875 shares at DKK 636.50 and

  • 5,964 shares at DKK 939.50.

Proceeds to the company are approximately DKK 103.3 million. The increase corresponds to approx. 0.6 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 10 of Executive Order no. 1526 of December 9, 2016 on Issuers' Disclosure Obligations, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 60,735,143, which is made up of 60,735,143 shares of a nominal value of DKK 1 each, corresponding to 60,735,143 votes.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 09

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Bredgade 34E

1260 Copenhagen K

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 mar
GEN
http://finans.dk/erhverv/ECE9448096/amerikansk-storinvestor-genmab-er-et-attraktivt-opkoeb-for-de-st..
4
26 mar
GEN
Solide kursstigninger er ikke at kimse af :-) Genmab har haft overskud i flere år og bruger deres o..
3
24 mar
GEN
du mener helt seriøst at Genmab har et efterslæb til C20........
3
07:52
GEN
Janssens:   http://medwatch.dk/secure/Medicinal___Biotek/article9465660.ece   Sklerose - Roche først..
2
07:47
GEN
Nyt forsøg under opstart, taget fra proinvestor.   https://clinicaltrials.gov/ct2/show/NCT03095118?t..
2
29 mar
GEN
Den tekniske konsolidering ser ud til at være overstået. Bunden er dobbelt testet i området 1390 og ..
2
26 mar
GEN
enig. Os fint at de benytter overskuddet til at fremskynde pipeline. 
2
26 mar
GEN
Jeg er godt tilfreds. Små 3000% de sidste fem år. Så pyt med et par kroner i udbytte.  
2
24 mar
GEN
Rising wedge identificeret som indikere kurs mod modstanden i 1488 inden for den naeste uges tid.
2
08:28
GEN
solsen:   "Man starter ikke et forsøg op, hvis der ikke er faglig begrundelse for at midlet har virk..
1

Vestas får tre ordrer i Kina - NY

29-03-2017 14:36:33
Vestas har fået tre vindmølleordrer til Kina, som alle er annonceret onsdag eftermiddag.Det danske vindmølleselskab skal levere møller til et projekt på 48 megawatt (MW) i Shandong-provinsen, til et 55 MW-projekt et uspecificeret sted i landet og til et andet 48 MW-projekt i Hebei-provinsen.Det fortæller Vestas i tre separate meddelelser.Det første projekt består af 22 V110-møller, der har en nomi..

Aktier/åbning: Mærsk trækker eliteindeks ned mens Carlsberg stiger

29-03-2017 09:36:06
Aktierne i A.P. Møller-Mærsk ligger omkring 150 kr. nede fra åbningen af aktiemarkedet onsdag - og det er lig det udbytte, der fragår aktierne. B-aktien falder med 1,1 pct. til 11.300 kr., mens A-aktien er 1,4 pct. nede i 10.880 kr.Samlet havde eliteindekset hikke fra morgenstunden - men efter 20 minutters handel har minusset bidt sig fast, og eliteindekset falder med 0,4 pct. til indeks 1069,4. D..

Aktier/tendens: Vestas kan komme i fokus i lysegrønt marked

29-03-2017 08:44:42
En større amerikansk satsning på olie og kul kan sætte Vestas i fokus fra morgenstunden, i et marked der ser ud til at åbne i plus.Præsident Donald Trump underskrev tirsdag et dekret om at tilbagerulle centrale dele af sin forgængers, Barack Obamas, klimalovgivning. Og Trump vil blandt andet fjerne et af Obamas tiltag, Clean Power Plan, fordi det ifølge dem er en hindring for olieboring og kulmine..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får tre ordrer i Kina - NY
2
Aktier/middag: Fransk storbank pifter efter Carlsberg - Pandora bakker
3
Genmab dropper nu også nyheder på dansk
4
Novo genindsender registreringsansøgning for Fiasp i USA - NY
5
TK Development kom endelig i plus og varsler ny fremgang

Relaterede aktiekurser

Genmab A/S 1.427,00 0,0% Aktiekurs uændret
Genmab AS DKK1 200,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. marts 2017 08:45:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB1 - 2017-03-30 08:45:59 - 2017-03-30 08:45:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x